COV2 is a nasal, investigational vaccine against COVID-19, based on a serotype 5 adenoviral vector producing the SARS-CoV-2 spike protein. In this trial, the primary comparison in terms of safety and immunogenicity will be between two different dose levels of COV2 booster vaccine (low, high), and two different administration methods (nasal drops, nasal spray). In addition, COV2 vaccine will also be evaluated in vaccine naive subjects.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Enrollment
40
Test article
Test article
Method of administration of test article
Kuopio University Hospital
Kuopio, Northern Savonia, Finland
Primary Immunogenicity
Percentage of subjects demonstrating a rise in SARS-CoV-2 serum NAb titers against Omicron BA.5 variant
Time frame: 28 days from baseline
Primary Safety
Treatment-emergent expected and unexpected adverse effects
Time frame: 28 days from baseline
Secondary Immunogenicity
Percentage of subjects demonstrating a rise in SARS-CoV-2 serum NAb titers against Wuhan and JN.1 variants
Time frame: 28 days from baseline
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Method of administration of test article